不眠症薬理学的治療市場- 世界の産業規模、シェア、動向、機会、予測、医薬品別、治療別、流通チャネル別、地域別、競合別、2020～2030年

不眠症薬理学的治療の世界市場規模は、2024年に38億1,000万米ドルとなり、2030年にはCAGR5.73％を反映して53億3,000万米ドルに達すると予測されています。

同市場は、世界中で睡眠障害の有病率が上昇していることを背景に、著しい成長を遂げています。ストレスの増加、ライフスタイルの変化、高齢化の進展などの要因により、不眠症の薬理学的治療に対する需要が高まっています。この市場には、ベンゾジアゼピン系催眠薬、非ベンゾジアゼピン系催眠薬、メラトニン受容体作動薬、オレキシン受容体拮抗薬など、幅広い処方薬と市販薬が含まれます。製薬会社は、従来の睡眠導入剤に関連する依存性や副作用に関する問題に対処するため、より安全で効果的な薬剤の開発に注力しています。新規治療に対する規制当局の承認と薬剤製剤の革新が市場の成長をさらに刺激し、患者に有効性の向上と副作用の軽減を提供しています。

未治療の不眠症がもたらす長期的な健康リスクに対する意識の高まりにより、診断件数が増加し、処方箋に基づく解決策への需要が高まっています。徐放性製剤や二重作用製剤の革新により、一晩中持続的な睡眠を確保することで治療成績が向上しています。さらに、個別化医療やバイオマーカーに基づく治療への傾向の高まりが、不眠症治療の状況を再構築しています。メラトニンを主成分とする睡眠補助剤のような、自然で習慣性のない解決策を求める消費者の需要が、新製品開発の原動力となっています。舌下錠や経皮パッチを含むドラッグデリバリーシステムの進歩は、多様な患者のニーズに応える治療の選択肢を広げています。製薬企業と研究機関の戦略的提携により、非鎮静性標的治療薬の開発が加速しており、市場拡大をさらに後押ししています。

主な市場促進要因

不眠症の有病率の増加

主な市場課題

長期使用に対する懸念

主な市場動向

医薬品の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の不眠症薬理学的治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 医薬品別（OTC医薬品、OTC睡眠補助薬、OTC睡眠サプリメント、処方薬）
  • 治療別（市販の睡眠薬、処方箋の睡眠薬）
  • 流通チャネル別（ドラッグストア、eコマース、病院薬局、小売薬局）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の不眠症薬理学的治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の不眠症薬理学的治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の不眠症薬理学的治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の不眠症薬理学的治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの不眠症薬理学的治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Merck & Co Inc
• Ebb Therapeutics Inc/US
• Pfizer Inc
• Sanofi SA
• Takeda Pharmaceutical Co Ltd
• Paratek Pharmaceuticals Inc
• Electromedical Products International Inc
• Meda Pharmaceuticals Inc
• Purdue Pharma LP
• Pernix Therapeutics Holdings Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

The global insomnia pharmacological treatment market was valued at USD 3.81 billion in 2024 and is projected to reach USD 5.33 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.73%. The market is experiencing significant growth, driven by the rising prevalence of sleep disorders across the globe. Factors such as increasing stress, lifestyle changes, and the growing aging population are intensifying the demand for pharmacological treatments for insomnia. This market includes a broad spectrum of prescription and over-the-counter drugs, including benzodiazepines, non-benzodiazepine hypnotics, melatonin receptor agonists, and orexin receptor antagonists. Pharmaceutical companies are focusing on developing safer, more effective medications to address issues related to dependency and adverse effects associated with traditional sleep aids. Regulatory approvals for novel treatments and innovations in drug formulations are further stimulating market growth, providing patients with improved efficacy and reduced side effects.

Heightened awareness about the long-term health risks of untreated insomnia is leading to more diagnoses and a growing demand for prescription-based solutions. Innovations in extended-release and dual-action formulations are improving treatment outcomes by ensuring sustained sleep throughout the night. Additionally, the growing trend toward personalized medicine and biomarker-based therapies is reshaping the landscape of insomnia treatment. Consumer demand for natural, non-habit-forming solutions, such as melatonin-based sleep aids, is driving new product development. Advances in drug delivery systems, including sublingual tablets and transdermal patches, are expanding treatment options to meet diverse patient needs. Strategic collaborations between pharmaceutical companies and research institutions are accelerating the development of non-sedative, targeted therapies, further supporting market expansion.

Key Market Drivers

Increasing Prevalence of Insomnia:

In today's fast-paced, digitally connected world, achieving quality sleep has become more challenging. Insomnia, characterized by persistent difficulties in falling asleep, staying asleep, or achieving restorative sleep, is on the rise. This increase in insomnia cases significantly contributes to the growth of the global pharmacological insomnia treatment market. Work-related stress, personal pressures, and constant exposure to screens have led to a substantial rise in sleep disturbances. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2020, approximately 14.5% of U.S. adults reported trouble falling asleep, and 17.8% had difficulty staying asleep regularly, underscoring the growing demand for treatment solutions.

Key Market Challenges

Concerns Over Long-Term Use:

One of the major challenges facing the global insomnia pharmacological treatment market is the concerns associated with the long-term use of medications. Prescription drugs used for insomnia treatment, such as benzodiazepines, non-benzodiazepine hypnotics, and certain antidepressants, can pose significant risks when used over extended periods. Prolonged use can lead to tolerance, dependency, withdrawal symptoms, and cognitive impairments. Over time, patients may require higher doses to achieve the same therapeutic effects, potentially leading to misuse or addiction. Furthermore, the risk of rebound insomnia when discontinuing these medications can worsen sleep disturbances. Long-term use of sedative-hypnotic medications has also been linked to adverse health effects, including cognitive decline and an increased risk of falls, particularly among elderly patients. Regulatory agencies like the U.S. FDA and the European Medicines Agency (EMA) have raised concerns about these risks, leading to stricter guidelines and closer scrutiny of chronic insomnia management.

As awareness of these issues grows, healthcare providers are exploring alternative treatments, such as cognitive behavioral therapy for insomnia (CBT-I) and lifestyle interventions, before resorting to long-term pharmacological solutions. Pharmaceutical companies face the challenge of developing new insomnia treatments that minimize dependency risks and cognitive side effects, while maintaining their effectiveness. These concerns are influencing prescription patterns, regulatory policies, and patient preferences, thereby shaping the future trajectory of the insomnia pharmacological treatment market.

Key Market Trends

Advancements in Pharmaceuticals:

The field of sleep disorders, particularly insomnia, has long been elusive, but recent advancements in pharmaceuticals are providing new insights into effective treatment options. These innovations are transforming insomnia management, offering hope and relief to individuals who have long struggled with sleep disturbances. Modern research has led to the development of new insomnia medications that are not only more effective but also safer, with fewer adverse side effects, making them more attractive to both patients and healthcare providers.

In-depth understanding of sleep regulation mechanisms has enabled the creation of targeted therapies that address specific aspects of insomnia, such as difficulties falling or staying asleep, providing more personalized and effective treatment options. Newer drugs are reducing the risks of dependency that plagued earlier sleep medications like benzodiazepines. Furthermore, some newer insomnia treatments offer longer-lasting effects, supporting sustained and restorative sleep throughout the night, improving the overall sleep experience.

Another key area of focus is minimizing next-day impairments, such as drowsiness and cognitive deficits, allowing individuals to maintain their daily activities. Advanced insomnia medications are also addressing comorbidities such as anxiety, depression, or chronic pain, offering a holistic approach to treatment.

Key Market Players:

• Merck & Co Inc.
• Ebb Therapeutics Inc. (USA)
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Paratek Pharmaceuticals Inc.
• Electromedical Products International Inc.
• Meda Pharmaceuticals Inc.
• Purdue Pharma LP
• Pernix Therapeutics Holdings Inc.

Report Scope: This report segments the global insomnia pharmacological treatment market into various categories, including industry trends and detailed analysis of the following areas:

By Drug:

• Over-the-Counter (OTC) Drugs
• OTC Sleep Aids
• OTC Sleep Supplements
• Prescription Drugs

By Treatment:

• Over-the-Counter Sleep Aids
• Prescription Sleep Aids

By Distribution Channel:

• Drug Stores
• E-Commerce
• Hospital Pharmacies
• Retail Pharmacies

By Region:

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Italy, Spain)
• Asia-Pacific (China, Japan, India, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape: In-depth analysis of leading companies in the global insomnia pharmacological treatment market.

Available Customizations: TechSci Research offers customized reports based on specific company needs. Customization options include:

• Company Information: Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Insomnia Pharmacological Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug (OTC Drugs, OTC Sleep Aids, OTC Sleep Supplements, Prescription Drugs)
  • 5.2.2. By Treatment (Over-the-Counter Sleep Aids, Prescription Sleep Aids)
  • 5.2.3. By Distribution Channel (Drug Stores, E-Commerce, Hospital Pharmacies, Retail Pharmacies)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Insomnia Pharmacological Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug
  • 6.2.2. By Treatment
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Insomnia Pharmacological Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Insomnia Pharmacological Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Insomnia Pharmacological Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Distribution Channel

7. Europe Insomnia Pharmacological Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug
  • 7.2.2. By Treatment
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Insomnia Pharmacological Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Insomnia Pharmacological Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Insomnia Pharmacological Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Insomnia Pharmacological Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Insomnia Pharmacological Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Insomnia Pharmacological Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug
  • 8.2.2. By Treatment
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Insomnia Pharmacological Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Insomnia Pharmacological Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Insomnia Pharmacological Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Insomnia Pharmacological Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Insomnia Pharmacological Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Distribution Channel

9. South America Insomnia Pharmacological Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug
  • 9.2.2. By Treatment
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Insomnia Pharmacological Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Insomnia Pharmacological Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Insomnia Pharmacological Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Insomnia Pharmacological Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug
  • 10.2.2. By Treatment
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Insomnia Pharmacological Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Insomnia Pharmacological Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Insomnia Pharmacological Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Merck & Co Inc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Ebb Therapeutics Inc/US
• 14.3. Pfizer Inc
• 14.4. Sanofi SA
• 14.5. Takeda Pharmaceutical Co Ltd
• 14.6. Paratek Pharmaceuticals Inc
• 14.7. Electromedical Products International Inc
• 14.8. Meda Pharmaceuticals Inc
• 14.9. Purdue Pharma LP
• 14.10. Pernix Therapeutics Holdings Inc

15. Strategic Recommendations

16. About Us & Disclaimer